Your Digital Self: Biotech stocks are in a post-pandemic slump and recovery in 2024 is questionable
Novavax NVAX, stands out as a stark reminder of the biotech sector’s faltering steps in 2023. Once renowned for its Nuvaxovid COVID-19 vaccine, the Maryland-based company is now grappling with financial issues, reflecting the broader challenges that continue to plague the pharmaceutical sector…
#novavaxnvax #nuvaxovidcovid19 #maryland #pfizerpfe #bntx #modernamrna #ftc #fda #ernstyoung #bdo